NEWARK, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the three and six months ended June 30, 2017.
“We reached a significant clinical milestone last month with the announcement of positive interim data from our ongoing Phase 2 clinical trial of seladelpar in patients with primary biliary cholangitis, or PBC,” said Sujal Shah, Interim President and Chief Executive Officer of CymaBay. “These results underscore the potent anti-cholestatic and anti-inflammatory effects of seladelpar.
